What is the recommended dose, indications, and contraindications for cinnarizine 20 mg combined with dimenhydrinate 40 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cinnarizine 20mg/Dimenhydrinate 40mg: Dosing, Indications, and Contraindications

The fixed-dose combination of cinnarizine 20mg and dimenhydrinate 40mg is indicated for the treatment of vertigo and motion sickness, administered as one tablet three times daily, and is contraindicated in neonates, patients with hypersensitivity to either component, and should be avoided in pregnancy.

Dosing

Standard adult dosing is one tablet (cinnarizine 20mg/dimenhydrinate 40mg) three times daily for up to 4 weeks 1, 2, 3, 4. This specific low-dose fixed combination has been extensively studied and demonstrates superior efficacy compared to higher-dose monotherapies.

For dimenhydrinate alone (when the combination is unavailable):

  • Adults: 50mg every 4 hours intramuscularly or intravenously (diluted in 10mL saline over 2 minutes); up to 100mg every 4 hours if drowsiness is acceptable 5
  • Pediatric: 1.25 mg/kg or 37.5 mg/m² four times daily, maximum 300mg daily 5
  • Oral antiemetic use: 25-50mg three times daily 6

Indications

Primary Indications (FDA-Approved for Dimenhydrinate Component)

  • Prevention and treatment of nausea, vomiting, or vertigo associated with motion sickness 5

Evidence-Based Uses for the Fixed Combination

  • Peripheral vestibular vertigo - The combination demonstrates superior efficacy versus betahistine 16mg, with significantly greater reduction in mean vertigo scores (p=0.035) 2
  • Central vestibular vertigo - Effective for vertigo of central origin 1, 3
  • Mixed central/peripheral vestibular disorders - The dual mechanism (peripheral calcium channel blockade via cinnarizine plus central H1-receptor antagonism via dimenhydrinate) addresses both pathways 4
  • Vertigo-associated nausea - Significantly reduces concomitant nausea compared to monotherapies (p<0.016) 4

The fixed combination shows symptom improvement within 1 week, with 74% of patients achieving complete symptom resolution (mean vertigo score = 0) by 4 weeks, significantly higher than comparators 1.

Off-Label Use (Dimenhydrinate Alone)

  • Nausea and vomiting in gastroparesis - Listed as treatment option at 25-50mg three times daily 6
  • Acute gastroenteritis with vomiting in adults - Antiemetics like dimenhydrinate facilitate oral rehydration 7
  • Nausea and vomiting in pregnancy - Dimenhydrinate is considered first-line antiemetic with safety data showing no increased risk of congenital malformations 8

Contraindications

Absolute Contraindications

  • Neonates - Dimenhydrinate is contraindicated due to benzyl alcohol content, which has been associated with fatal "Gasping Syndrome" in premature infants and low birth weight infants 5
  • Hypersensitivity to dimenhydrinate, diphenhydramine, 8-chlorotheophylline, or cinnarizine 5

Relative Contraindications and Precautions

  • Pregnancy - While dimenhydrinate alone is considered safe as first-line antiemetic 8, cinnarizine data in pregnancy are limited. Use only if benefit outweighs risk
  • Children <18 years - Antimotility/antiemetic agents should generally be avoided in acute diarrhea in this age group 7
  • Elderly patients - Use with caution; may require monitoring for increased sedation and anticholinergic effects
  • Renal impairment - No specific dose adjustments documented for the combination, but monitor for adverse effects
  • Concurrent CNS depressants - Additive sedation possible

Safety Profile

The fixed combination demonstrates excellent tolerability with only 2.4% of patients discontinuing due to adverse events across pooled trials 1. Nearly 98% of patients rated tolerability as "good" or "very good" 1, 2.

Common adverse effects are mild: drowsiness, dry mouth, and gastrointestinal symptoms. The low-dose combination (20mg/40mg) shows fewer adverse events than higher-dose monotherapies (cinnarizine 50mg or dimenhydrinate 100mg alone) 4.

Clinical Pearls

  • The 20mg/40mg fixed combination is specifically optimized - higher doses of individual components do not improve efficacy and increase adverse effects 4
  • Onset of action: Significant symptom reduction occurs within 1 week, with maximal benefit by 4 weeks 2, 9
  • The combination addresses both peripheral (cinnarizine's calcium channel blockade) and central (dimenhydrinate's H1-receptor antagonism) mechanisms of vertigo 3, 9
  • Gender differences may exist in treatment response, with some studies suggesting differential efficacy between males and females 9

References

8
Guideline

the management of nausea and vomiting in pregnancy and hyperemesis gravidarum (green-top guideline no. 69).

BJOG : an international journal of obstetrics and gynaecology, 2024

Related Questions

What are the indications and contraindications for the tablet containing cinnarizine 40 mg and diphenhydramine 20 mg?
Are there any drug interactions between cinnarizine, dimenhydrinate, and pregabalin?
What are the uses and contraindications of the combination of cinnarizine 20 mg and dimenhydrinate 40 mg?
How should cinnarizine be dosed for motion sickness and peripheral vestibular vertigo, and what are the safety precautions and contraindications?
What is the appropriate dose of cinnarizine for treating nausea during pregnancy?
Is it appropriate to combine metolazone with spironolactone, and how should serum potassium and renal function be monitored?
What are the admission criteria for patients with sepsis or septic shock, including organ dysfunction indicators such as a quick Sepsis‑Related Organ Failure Assessment (qSOFA) score of 2 or more, a full SOFA increase of ≥ 2 points, elevated lactate, hypotension, and other relevant clinical signs?
Should I add an ACE inhibitor (angiotensin‑converting enzyme inhibitor) or an ARB (angiotensin receptor blocker) before spironolactone in a patient with left ventricular ejection fraction of 50 % whose volume status is controlled on metolazone?
Can betahistine 16 mg be administered together with cinnarizine 20 mg and dimenhydrinate 40 mg?
What is the appropriate treatment for anxiety-induced nausea?
Is Adderall XR (mixed amphetamine salts) an immediate-release or extended-release formulation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.